{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0"},{"groupId":"OG001","value":"44.8"},{"groupId":"OG002","value":"35.5"}]}],"title":"Normal"},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.7"},{"groupId":"OG001","value":"40.8"},{"groupId":"OG002","value":"37.2"}]}],"title":"Mildly restricted"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.5"},{"groupId":"OG001","value":"12.0"},{"groupId":"OG002","value":"14.0"}]}],"title":"Moderately restricted"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8"},{"groupId":"OG001","value":"2.4"},{"groupId":"OG002","value":"12.4"}]}],"title":"Severely restricted"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"0.8"}]}],"title":"Immobilized"}],"denoms":[{"counts":[{"groupId":"OG000","value":"131"},{"groupId":"OG001","value":"129"},{"groupId":"OG002","value":"129"}],"units":"Participants"}],"description":"The study physician assessed the patient's range of motion of the most affected joint on a 5 point Likert scale (normal, mildly restricted, moderately restricted, severely restricted and immobilized).","groups":[{"description":"Patients on this arm received 150 mg subcutaneously (s.c.) at randomization and upon new flare. The doses were provided as pre-filled syringes. The patients were given 3 injections: two placebo and one active drug.","id":"OG000","title":"Canakinumab, Pre-filled Syringes (PFS)"},{"description":"The patients on this arm received 150 mg s.c. at randomization and upon new flare. The doses were provided as lyophilized power and had to be reconstituted with water for injection before application. The patients were given 3 injections: two placebo and one active drug.","id":"OG001","title":"Canakinumab, Lyophilizate (LYO)"},{"description":"The patients on this arm received 40 mg intramuscular (i.m.) at randomization and upon new flare. The patients were given 3 injections: two placebo and one active drug.","id":"OG002","title":"Triamcinolone Acetonide"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set: The Full Analysis Set (FAS) consisted of all patients as randomized that had at least one dose of study drug. Following the intent-to-treat principle, patients were analyzed according to the treatment they were assigned to at randomization.","reportingStatus":"POSTED","timeFrame":"72 hours","title":"Physician's Assessment of Range of Motion of the Most Affected Joint","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}